C$0.035 AIML.CN AI/ML Innovations Inc. CNQ 28 Jan 2026 Market Hours: Data-driven outlook
We see AIML.CN stock trading at C$0.035 on 28 Jan 2026 during market hours, with 1,046,112 shares changing hands and a 50-day average price at C$0.0376. This small-cap healthcare AI name combines wearable data and digital-health software but shows weak financials: EPS -0.03, PE -1.17, and market cap about C$5,889,240.00. Volume spikes and wide spreads make near-term trading volatile. We outline valuation, technicals, and a model-based forecast to help frame risk versus potential catalysts for AI-focused portfolios.
Company profile and recent trading for AIML.CN stock
AI/ML Innovations Inc. (AIML.CN) is listed on CNQ in Canada and develops AI and machine-learning enabled personal health monitoring and wearable solutions. Today the stock sits at C$0.035 with a day range C$0.03–C$0.035, a 52-week high of C$0.14, and 52-week low C$0.03.
Trading volume is elevated at 1,046,112 versus an average of 380,122, giving a relative volume near 2.75 which signals short-term attention from traders.
Financial snapshot and key ratios in AIML.CN analysis
AIML.CN shows strained fundamentals: trailing EPS -0.03, PE -1.17, price-to-sales 35.00, and price-to-book 4.58. The company reports working capital and cash buffers with cashPerShare 0.005323986, current ratio 2.09, and debt-to-equity 0.11, which contrast with persistent negative margins.
Receivables are unusually high relative to sales (days sales outstanding 575.81), pointing to collection and revenue-recognition pressure that weighs on near-term earnings recovery.
Technical setup and short-term trading signals for AIML.CN stock
Momentum indicators are subdued: RSI 40.70 and ADX 14.53 indicate a weak trend and limited directional conviction. Bollinger Bands sit at C$0.03–C$0.04 and the 50-day average price is C$0.0376, just above the current price, which signals short-term resistance.
Given elevated volume and a volatile price history (three-month change -36.36%, one-year change -65.00%), traders should expect larger intraday swings and manage position sizing accordingly.
Meyka AI grade and model forecast for AIML.CN stock
Meyka AI rates AIML.CN with a score out of 100: 58.22, Grade C+, Suggestion HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.
Meyka AI’s forecast model projects a 12-month value of C$0.017 versus the current C$0.035, implying an expected decline near -51.26%. Short-term model outputs include a monthly projection at -C$0.02, highlighting downside risk. Forecasts are model-based projections and not guarantees.
Valuation, sector context and AIML.CN stock risks
Within Healthcare, AIML.CN’s price-to-sales 35.00 and negative margins stand out versus sector averages, and research-and-development is modest at 5.21% of revenue. The company’s enterprise value C$4,952,087.00 and thin market cap place it in the micro-cap risk bucket, where liquidity and information flow are limited.
Key risks include continued operating losses, customer adoption cycles for wearable devices, and long days-sales-outstanding. Positive catalysts would require contract wins, clearer recurring revenue, or technology partnerships.
Price targets, scenarios and trading strategy for AIML.CN stock
We outline three scenario price targets to frame risk-reward: Bear C$0.02 (down -42.86%), Base C$0.04 (up +14.29%), Bull C$0.10 (up +185.71%). Each target assumes differing outcomes on revenue traction and funding.
For AI-stock strategies, consider small, size-limited positions, strict stop-losses, and event-driven entry around product announcements or financings. Use liquidity-aware limit orders on CNQ and review filings before trading. For more background see AI sector news from Reuters and broader AI coverage at the WSJ.
Final Thoughts
AIML.CN stock trades at C$0.035 on CNQ with micro-cap liquidity and clearly negative margins, making it a high-risk AI healthcare exposure for traders and investors. Meyka AI’s proprietary grade of 58.22 (C+, HOLD) flags mixed signals: modest cash buffers and a current ratio near 2.09 but weak revenue metrics and stretched receivables. Our model projects a 12-month value near C$0.017, implying about -51.26% downside from today; this is a model projection, not a guarantee. Short term, volume spikes create trading opportunities but also higher execution risk. If you hold AIML.CN for AI/healthcare upside, look for concrete revenue growth, tighter receivables, or strategic partnerships before increasing exposure. For active traders, treat positions as speculative, size them conservatively, and monitor company updates on the Meyka AI platform at https://meyka.ai/stocks/AIML.CN and regulatory filings for timely catalysts.
FAQs
What is the current price and market activity for AIML.CN stock?
AIML.CN is trading at C$0.035 with a volume of 1,046,112 versus average volume 380,122, and a day range of C$0.03–C$0.035 on CNQ in Canada. Volume suggests short-term interest and volatility.
How does Meyka AI grade AIML.CN and what does it mean?
Meyka AI rates AIML.CN 58.22 out of 100, Grade C+ with a HOLD suggestion. The grade combines benchmark and sector comparisons, financial growth, key metrics, forecasts and analyst signals; it is informational, not investment advice.
What are the main risks for AIML.CN stock to consider?
Major risks include persistent operating losses (EPS -0.03), high days sales outstanding (575.81), thin market cap and liquidity, and slow commercial adoption of its AI-enabled health products.
Does Meyka AI provide a forecast for AIML.CN stock?
Yes. Meyka AI’s forecast model projects a 12-month value of C$0.017 versus the current C$0.035, implying about -51.26% downside. Forecasts are model-based projections and not guarantees.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
